- Home
- HTGC vs PTGX Comparison
HTGC vs PTGX Comparison
Compare HTGC & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTGC
- PTGX
- Stock Information
- Founded
- HTGC 2003
- PTGX 2006
- Country
- HTGC United States
- PTGX United States
- Employees
- HTGC N/A
- PTGX N/A
- Industry
- HTGC Investment Managers
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- HTGC Finance
- PTGX Health Care
- Exchange
- HTGC Nasdaq
- PTGX Nasdaq
- Market Cap
- HTGC 3.2B
- PTGX 3.3B
- IPO Year
- HTGC 2005
- PTGX 2016
- Fundamental
- Price
- HTGC $19.44
- PTGX $55.15
- Analyst Decision
- HTGC Buy
- PTGX Strong Buy
- Analyst Count
- HTGC 8
- PTGX 9
- Target Price
- HTGC $20.94
- PTGX $67.11
- AVG Volume (30 Days)
- HTGC 945.2K
- PTGX 790.5K
- Earning Date
- HTGC 07-31-2025
- PTGX 08-05-2025
- Dividend Yield
- HTGC 9.67%
- PTGX N/A
- EPS Growth
- HTGC N/A
- PTGX N/A
- EPS
- HTGC 1.33
- PTGX 0.86
- Revenue
- HTGC $491,549,000.00
- PTGX $207,801,000.00
- Revenue This Year
- HTGC $7.31
- PTGX N/A
- Revenue Next Year
- HTGC $9.64
- PTGX $53.09
- P/E Ratio
- HTGC $14.60
- PTGX $63.94
- Revenue Growth
- HTGC 3.02
- PTGX N/A
- 52 Week Low
- HTGC $15.65
- PTGX $32.50
- 52 Week High
- HTGC $22.04
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- HTGC 69.49
- PTGX 56.72
- Support Level
- HTGC $18.86
- PTGX $51.55
- Resistance Level
- HTGC $19.65
- PTGX $57.73
- Average True Range (ATR)
- HTGC 0.23
- PTGX 1.74
- MACD
- HTGC 0.03
- PTGX -0.07
- Stochastic Oscillator
- HTGC 82.23
- PTGX 69.13
About HTGC Hercules Capital Inc.
Hercules Capital Inc is a specialty finance company that provides senior secured loans to high-growth, venture capital-backed companies in various technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries, including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.